Friday, May 01, 2020 1:58:42 PM
Diwan has made a FREAKING FORTUNE doing what he's been doing.
Consider that almost all of that accumulated deficit of $100,000,000.00 was paid by NNVC to Theracour. 30% of that ain't chicken feed.
The there is his and Meeta's combined NNVC salaries and compensation, of almost $1M/year:
https://www.erieri.com/executive/salary/anil-diwan-3j6u
https://www.erieri.com/executive/salary/meeta-vyas-8u3h
That's quite a bit of hay accumulated over 15 years.
And lord knows how much their combined Theracour salaries are on top of all this. Maybe a couple million more each year.
No rational person would risk spending all that money on a very risky drug-development program when they could just transfer it to their bank accounts as has Diwan. They would have to be certain of having something huge in hand, with a near certainty of success, like a "penicillin for viruses" that had "no toxic effects".
Consider that almost all of that accumulated deficit of $100,000,000.00 was paid by NNVC to Theracour. 30% of that ain't chicken feed.
The there is his and Meeta's combined NNVC salaries and compensation, of almost $1M/year:
https://www.erieri.com/executive/salary/anil-diwan-3j6u
https://www.erieri.com/executive/salary/meeta-vyas-8u3h
That's quite a bit of hay accumulated over 15 years.
And lord knows how much their combined Theracour salaries are on top of all this. Maybe a couple million more each year.
No rational person would risk spending all that money on a very risky drug-development program when they could just transfer it to their bank accounts as has Diwan. They would have to be certain of having something huge in hand, with a near certainty of success, like a "penicillin for viruses" that had "no toxic effects".
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
